PICO Advisory Sub-Committee (PASC) – Applications considered

• 1751 – Valoctocogene roxaparvovec gene therapy for haemophilia A
• 1766 – Genetic testing to detect AKT-pathway alterations in patients with hormone receptor-positive, HER2-negative advanced breast cancer, to determine eligibility for PBS subsidised capivasertib treatment.
• 1767 – Immunohistochemistry testing for Claudin 18 expression in patients with gastric or gastro-oesophageal junction cancers, to determine eligibility for PBS subsidised zolbetuximab treatment
• 1769 – Human leukocyte antigen testing for sensitivity to carbamazepine in patients with epilepsy
• 1770 – Valve-in-valve transcatheter aortic valve implantation using a balloon-expanding transcatheter heart valve system
• 1772 – Single chamber leadless pacing with atrio-ventricular synchronous pacing in pattients with bradycardia
• 1773 – Autologous chondrocyte implantation for symptomatic articular cartilage defects greater than 2cm² of the knee
• 1774 – Newborn bloodspot screening for glycogen storage disease, Type II (Pompe disease)
• 1775 – Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I)
• 1776 – Newborn bloodspot screening for mucopolysaccharidosis, Type II (MPS II)

Consultation Input:

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.

Consultation for the April 2024 PASC meeting closed on 15 March 2024.

Further information on MSAC’s consultation process is available on the MSAC website.